Dermatologic and Ophthalmic Drugs Advisory Committee explained

The Dermatologic And Ophthalmic Drugs Advisory Committee (DODAC) receives requests for technical and clinical evaluation of new drugs by the U.S. Food and Drug Administration (FDA). The committee, consisting of members from academic and clinical dermatology, ophthalmology, biostatistics, the general public, and the pharmaceutical industry, makes non-binding recommendations to both the CDER and CBER divisions of the FDA about the advisability of approving new medications to treat dermatologic and ophthalmic conditions.

External links

• Dermatologic And Ophthalmic Drugs Advisory Committee, official webpage: https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisoryCommittee/default.htm
• FDA Advisory Committees Calendar (including DODAC): https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm